通过激活PPARγ,普尼卡林可以改善因高脂血症和高血糖症引起的血管内皮质细胞亡和功能障碍
Xu Chen1, Xiaohua Wei1, Wanwan Yuan2
1Department of Pharmacy, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China.
International immunopharmacology
|September 2, 2025
概括
普尼卡林 (PUN) 通过减少炎症和热来防止血管内皮功能障碍. 这种天然化合物增强了内皮功能,并为糖尿病相关的血管并发症提供了潜在的治疗方法.
科学领域:
- 心血管研究
- 细胞生物学
- 药理学
背景情况:
- 由炎症引起的血管内皮功能障碍是心血管疾病的关键因素,
- 炎症性细胞死亡的Pyroptosis被越来越多地认为是内皮功能障碍的关键因素.
- 植物化合物尼卡林 (PUN) 具有抗炎和抗炎症作用,但其在内皮细胞中的作用需要澄清.
研究的目的:
- 研究Punicalin (PUN) 对血管内皮功能障碍的保护机制.
- 在实验模型中评估PUN对热和内皮功能的影响.
主要方法:
- 由高脂肪和高葡萄糖条件引起的内皮功能障碍模型的开发.
- 评估PUN对氧化 (NO) 生产,内甲素-1 (ET-1) 水平以及PI3K/Akt/eNOS通路的影响.
- 对热致死标记物 (NLRP3,caspase-1,GSDMD-N,IL-1β,IL-18) 和FOXO1酸化和局部化的分析.
主要成果:
- 通过增加NO的产生,降低ET-1,并激活PI3K/Akt/eNOS通路,PUN增强了内皮功能.
- 通过减少活性氧物种和抑制NLRP3,caspase-1,GSDMD-N,IL-1β和IL-18,PUN抑制了高脂肪/高葡萄糖诱导的烧死.
- PUN促进了FOXO1的酸化,减少了其核积累,并抑制了其与GSDMD的相互作用,从而防止了热.
结论:
- 普尼卡林通过PI3K/ Akt/ eNOS通路的激活和NLRP3- caspase- 1介导的灭来缓解内皮功能障碍.
- 对于预防与糖尿病相关的血管并发症,PUN具有潜在的治疗作用.
相关概念视频
Cell Specific Gene Expression
13.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Peripheral Artery Disease I: Introduction
32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32


